Skip to main content
Caplight Logo









Dewpoint Therapeutics

Dewpoint Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://dewpointx.com/

Last Round

Series B

Jul 13, 2026

Total Funding Raised

$346.1M

Company Overview

Dewpoint Therapeutics is a biotechnology company that develops small molecule medicines targeting biomolecular condensates to treat intractable conditions including cancer, neurodegeneration, and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biomolecular condensatesdrug discoverysmall molecule modulatorscondensate biologyundruggable targetsAI drug discoverybiotech platformphenomicsdrug licensingmembrane-less organellesoncology therapeuticsneurodegeneration researchin-silico drug designpharma R&D partnershipsbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Dewpoint Therapeutics Comparables

Compare Dewpoint Therapeutics with similar companies based on industry and business-model similarity.

Dewpoint Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Transition Bio
88%
Nereid Therapeutics
84%
ETERN Therapeutics
84%

Dewpoint Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 13, 2026
Series DSep 10, 2025
Series CFeb 3, 2022
Series BSep 29, 2020
Series AJan 30, 2019

Key People

Founding team and executive leadership

Ameet Nathwani

Chief Executive Officer and President

Executive Team

Dewpoint Therapeutics Investors

Notable investors and investment history

Dewpoint Therapeutics investors
InvestorRounds
EcoR1 CapitalSeries C, Series B, Series A
SoftBank Investment AdvisersSeries C
Maverick VenturesSeries C, Series A, Series B
Bencao CapitalSeries C
Innovation EndeavorsSeries B
ARCH Venture PartnersSeries C, Series B
SoftBank GroupSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 21, 2026

    Presented preclinical data on Oral MYC condensate modulator at AACR 2026.

  • Apr 21, 2026

    Presented data at the AACR 2026 conference.

Dewpoint Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Dewpoint Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Dewpoint Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range57
Year Founded2018
Last FundingJul 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?